483 Initial safety results and immune responses induced by a novel human papillomavirus (HPV)-specific gorilla adenovirus immunotherapy vaccine, PRGN-2009, in patients with advanced HPV-associated cancers
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1819004828971433984 |
|---|---|
| author | Jeffrey Schlom Ravi Madan Seth Steinberg James Gulley Caroline Jochems Renee Donahue Sheri McMahon Lisa Cordes Julius Strauss Fatima Karzai Jason Redman Charalampos Floudas Clint Allen Douglas Brough Amy Lankford Jenn Marte |
| author_facet | Jeffrey Schlom Ravi Madan Seth Steinberg James Gulley Caroline Jochems Renee Donahue Sheri McMahon Lisa Cordes Julius Strauss Fatima Karzai Jason Redman Charalampos Floudas Clint Allen Douglas Brough Amy Lankford Jenn Marte |
| author_sort | Jeffrey Schlom |
| collection | DOAJ |
| first_indexed | 2024-12-20T23:43:06Z |
| format | Article |
| id | doaj.art-8a5d294ad1844c6792d8983bd9216c7c |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-12-20T23:43:06Z |
| publishDate | 2021-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-8a5d294ad1844c6792d8983bd9216c7c2022-12-21T19:23:02ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262021-11-019Suppl 210.1136/jitc-2021-SITC2021.483483 Initial safety results and immune responses induced by a novel human papillomavirus (HPV)-specific gorilla adenovirus immunotherapy vaccine, PRGN-2009, in patients with advanced HPV-associated cancersJeffrey Schlom0Ravi Madan1Seth Steinberg2James Gulley3Caroline Jochems4Renee Donahue5Sheri McMahon6Lisa Cordes7Julius Strauss8Fatima Karzai9Jason Redman10Charalampos Floudas11Clint Allen12Douglas Brough13Amy Lankford14Jenn Marte15Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland, USAAff2 grid.48336.3a0000000419368075National Cancer Institute Bethesda MD USAGenitourinary Malignancies, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USANIH, Bethesda, MD, USALaboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland, USANIH, Bethesda, MD, USAGenitourinary Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USAGenitourinary Malignancies, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USALaboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland, USAGenitourinary Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USAGenitourinary Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USAGenitourinary Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USASection on Translational Tumor Immunology, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD, USA3Precigen, Inc., Germantown, MD, USA3Precigen, Inc., Germantown, MD, USA1NCI, NIH, Bethesda, MD, USA |
| spellingShingle | Jeffrey Schlom Ravi Madan Seth Steinberg James Gulley Caroline Jochems Renee Donahue Sheri McMahon Lisa Cordes Julius Strauss Fatima Karzai Jason Redman Charalampos Floudas Clint Allen Douglas Brough Amy Lankford Jenn Marte 483 Initial safety results and immune responses induced by a novel human papillomavirus (HPV)-specific gorilla adenovirus immunotherapy vaccine, PRGN-2009, in patients with advanced HPV-associated cancers Journal for ImmunoTherapy of Cancer |
| title | 483 Initial safety results and immune responses induced by a novel human papillomavirus (HPV)-specific gorilla adenovirus immunotherapy vaccine, PRGN-2009, in patients with advanced HPV-associated cancers |
| title_full | 483 Initial safety results and immune responses induced by a novel human papillomavirus (HPV)-specific gorilla adenovirus immunotherapy vaccine, PRGN-2009, in patients with advanced HPV-associated cancers |
| title_fullStr | 483 Initial safety results and immune responses induced by a novel human papillomavirus (HPV)-specific gorilla adenovirus immunotherapy vaccine, PRGN-2009, in patients with advanced HPV-associated cancers |
| title_full_unstemmed | 483 Initial safety results and immune responses induced by a novel human papillomavirus (HPV)-specific gorilla adenovirus immunotherapy vaccine, PRGN-2009, in patients with advanced HPV-associated cancers |
| title_short | 483 Initial safety results and immune responses induced by a novel human papillomavirus (HPV)-specific gorilla adenovirus immunotherapy vaccine, PRGN-2009, in patients with advanced HPV-associated cancers |
| title_sort | 483 initial safety results and immune responses induced by a novel human papillomavirus hpv specific gorilla adenovirus immunotherapy vaccine prgn 2009 in patients with advanced hpv associated cancers |
| work_keys_str_mv | AT jeffreyschlom 483initialsafetyresultsandimmuneresponsesinducedbyanovelhumanpapillomavirushpvspecificgorillaadenovirusimmunotherapyvaccineprgn2009inpatientswithadvancedhpvassociatedcancers AT ravimadan 483initialsafetyresultsandimmuneresponsesinducedbyanovelhumanpapillomavirushpvspecificgorillaadenovirusimmunotherapyvaccineprgn2009inpatientswithadvancedhpvassociatedcancers AT sethsteinberg 483initialsafetyresultsandimmuneresponsesinducedbyanovelhumanpapillomavirushpvspecificgorillaadenovirusimmunotherapyvaccineprgn2009inpatientswithadvancedhpvassociatedcancers AT jamesgulley 483initialsafetyresultsandimmuneresponsesinducedbyanovelhumanpapillomavirushpvspecificgorillaadenovirusimmunotherapyvaccineprgn2009inpatientswithadvancedhpvassociatedcancers AT carolinejochems 483initialsafetyresultsandimmuneresponsesinducedbyanovelhumanpapillomavirushpvspecificgorillaadenovirusimmunotherapyvaccineprgn2009inpatientswithadvancedhpvassociatedcancers AT reneedonahue 483initialsafetyresultsandimmuneresponsesinducedbyanovelhumanpapillomavirushpvspecificgorillaadenovirusimmunotherapyvaccineprgn2009inpatientswithadvancedhpvassociatedcancers AT sherimcmahon 483initialsafetyresultsandimmuneresponsesinducedbyanovelhumanpapillomavirushpvspecificgorillaadenovirusimmunotherapyvaccineprgn2009inpatientswithadvancedhpvassociatedcancers AT lisacordes 483initialsafetyresultsandimmuneresponsesinducedbyanovelhumanpapillomavirushpvspecificgorillaadenovirusimmunotherapyvaccineprgn2009inpatientswithadvancedhpvassociatedcancers AT juliusstrauss 483initialsafetyresultsandimmuneresponsesinducedbyanovelhumanpapillomavirushpvspecificgorillaadenovirusimmunotherapyvaccineprgn2009inpatientswithadvancedhpvassociatedcancers AT fatimakarzai 483initialsafetyresultsandimmuneresponsesinducedbyanovelhumanpapillomavirushpvspecificgorillaadenovirusimmunotherapyvaccineprgn2009inpatientswithadvancedhpvassociatedcancers AT jasonredman 483initialsafetyresultsandimmuneresponsesinducedbyanovelhumanpapillomavirushpvspecificgorillaadenovirusimmunotherapyvaccineprgn2009inpatientswithadvancedhpvassociatedcancers AT charalamposfloudas 483initialsafetyresultsandimmuneresponsesinducedbyanovelhumanpapillomavirushpvspecificgorillaadenovirusimmunotherapyvaccineprgn2009inpatientswithadvancedhpvassociatedcancers AT clintallen 483initialsafetyresultsandimmuneresponsesinducedbyanovelhumanpapillomavirushpvspecificgorillaadenovirusimmunotherapyvaccineprgn2009inpatientswithadvancedhpvassociatedcancers AT douglasbrough 483initialsafetyresultsandimmuneresponsesinducedbyanovelhumanpapillomavirushpvspecificgorillaadenovirusimmunotherapyvaccineprgn2009inpatientswithadvancedhpvassociatedcancers AT amylankford 483initialsafetyresultsandimmuneresponsesinducedbyanovelhumanpapillomavirushpvspecificgorillaadenovirusimmunotherapyvaccineprgn2009inpatientswithadvancedhpvassociatedcancers AT jennmarte 483initialsafetyresultsandimmuneresponsesinducedbyanovelhumanpapillomavirushpvspecificgorillaadenovirusimmunotherapyvaccineprgn2009inpatientswithadvancedhpvassociatedcancers |